The Lancet September 07, 2002

Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial

Fox KA, Poole-Wilson PA, Henderson RA, et al.

Bottom Line

In patients with non-ST-elevation acute coronary syndromes, an early interventional strategy significantly reduced the rate of refractory angina at four months, but did not significantly reduce the combined rate of death or non-fatal myocardial infarction at one year compared to a conservative strategy.

Key Findings

1. At 4 months, the co-primary composite endpoint of death, non-fatal MI, or refractory angina was significantly lower in the interventional group compared to the conservative group (9.6% vs 14.5%; RR 0.66, p=0.001).

2. This 4-month benefit was primarily driven by a marked reduction in the incidence of refractory angina (6.5% in the interventional group vs 11.6% in the conservative group; RR 0.47, p<0.0001).

3. At 1 year, the second co-primary composite endpoint of death or non-fatal MI showed no significant difference between the two strategies (7.6% vs 8.3%; p=0.58).

4. At 1 year, individual rates of death (4.6% vs 3.9%, p=0.50) and myocardial infarction (3.8% vs 4.8%, p=0.29) did not differ significantly between the interventional and conservative arms.

Study Design

Design

RCT

Open-Label

Sample

1,810

Patients

Duration

1 yr

Median

Setting

Multicenter, UK

Population Patients with suspected cardiac chest pain at rest and documented evidence of coronary artery disease (such as ischemic ECG changes, pathological Q waves, or prior angiographically proven coronary artery disease).

Intervention Early interventional strategy: routine coronary angiography within 72 hours of randomization, followed by appropriate myocardial revascularization (PCI or CABG).

Comparator Conservative strategy: initial optimal medical therapy, with ischemia-driven or symptom-driven coronary angiography.

Outcome Co-primary endpoints: a composite of death, non-fatal myocardial infarction, or refractory angina at 4 months; and a composite of death or non-fatal myocardial infarction at 1 year.

Study Limitations

• The open-label nature of the trial could have influenced the reporting and adjudication of 'refractory angina', which was the primary driver of the early composite endpoint benefit.

• The 1-year follow-up for the hard endpoints of death or MI was relatively short to capture late mortality benefits (which only emerged in subsequent 5-year follow-up publications).

• The trial was conducted before the universal adoption of modern high-intensity statins, potent P2Y12 inhibitors, and newer-generation drug-eluting stents.

• The overall risk profile of the enrolled patients was relatively moderate compared to other ACS trials, which likely diluted the early mortality and MI benefits of an invasive approach.

Clinical Significance

RITA-3 demonstrated that a routine early invasive strategy in moderate-risk NSTE-ACS patients is highly effective at relieving ischemia and reducing the need for readmission due to refractory angina. Although it did not show an early survival benefit at 1 year, the findings reinforced evolving guidelines that favored an invasive approach to improve symptom control and quality of life, complementing the hard-outcome benefits seen in higher-risk cohorts in parallel trials.

Historical Context

In the late 1990s and early 2000s, the management of NSTE-ACS was highly debated. Early trials like VANQWISH showed no benefit and potential harm with early invasive strategies, but subsequent trials like FRISC-II (1999) and TACTICS-TIMI 18 (2001) showed clear benefits in the era of stents and aggressive antiplatelet therapy. RITA-3 was initiated to provide definitive data in a broad, representative UK population where invasive facilities were less routinely utilized. Its findings helped solidify the global shift toward routine early invasive management for intermediate to high-risk ACS patients.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

In patients with Non-ST-Elevation Acute Coronary Syndromes (NSTE-ACS) like those in the RITA 3 trial, why might an early invasive strategy not show the same immediate mortality benefit as primary PCI does in STEMI patients?

Key Response

STEMI typically involves a completely occlusive thrombus requiring immediate mechanical reperfusion to salvage dying myocardium. In contrast, NSTE-ACS usually involves a partially occlusive or dynamic thrombus where initial stabilization with antithrombotics and anti-ischemics (the conservative approach) can be highly effective. This pathophysiological difference explains why routine early intervention in NSTE-ACS primarily improves symptoms (refractory angina) rather than drastically reducing short-term mortality.

Resident

Given that RITA 3 showed a reduction in refractory angina but no significant difference in death or MI at 1 year, how should we use clinical risk scores (like GRACE or TIMI) to decide which NSTE-ACS patients should undergo an early invasive strategy today?

Key Response

Because routine invasive management does not confer a mortality benefit for all-comers with NSTE-ACS, risk stratification is crucial. High-risk patients (e.g., elevated troponins, dynamic ST-segment changes, high GRACE score >140) have a higher incidence of hard events and derive a survival benefit from early invasive management. Low-risk patients may safely be managed with an ischemia-guided (conservative) approach, as demonstrated by the lack of death/MI benefit in the broader RITA 3 cohort.

Fellow

RITA 3, unlike FRISC-II and TACTICS-TIMI 18, failed to show a significant reduction in death or MI with an invasive strategy at 1 year. What differences in trial design, patient population, or concurrent medical therapies explain these divergent results?

Key Response

The divergence is largely driven by patient risk profiles and concurrent therapies. RITA 3 included a lower-risk population compared to FRISC-II, diluting the potential absolute risk reduction for death/MI. Furthermore, differences in the systematic use of modern antiplatelet therapies (like glycoprotein IIb/IIIa inhibitors in TACTICS-TIMI 18) and variations in the definition of periprocedural MI significantly impacted the composite hard endpoints across these landmark trials.

Attending

When counseling a clinically stable NSTE-ACS patient without high-risk features whose primary concern is quality of life, how do you frame the findings of RITA 3 regarding symptom relief versus the lack of a distinct 1-year mortality benefit?

Key Response

It requires shared decision-making, framing the invasive procedure not as a life-saving measure, but as a quality-of-life intervention. The attending should explain that medical therapy is very safe and effectively protects against heart attacks and death (the conservative arm outcome), but proceeding with an angiogram and possible stent significantly lowers the chance of recurrent chest pain and repeat hospitalizations (the primary benefit seen in RITA 3).

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The RITA 3 trial utilized co-primary endpoints: a composite of death/MI at 1 year, and refractory angina at 4 months. What are the statistical and clinical pitfalls of including a subjective 'soft' endpoint (angina) alongside hard clinical endpoints (death/MI) in an unblinded trial of invasive procedures?

Key Response

In an unblinded trial, patients and physicians know who received the intervention. This introduces significant ascertainment bias for subjective endpoints like 'refractory angina'—conservative-arm patients and their physicians might have a lower threshold to report or diagnose recurrent angina, artificially inflating the benefit of the invasive strategy. Meanwhile, the hard, objective endpoints (death/MI) remain unaffected by this bias but may be statistically underpowered.

Journal Editor

As a peer reviewer, how would you critically evaluate the crossover rate from the conservative to the invasive arm in RITA 3, and what impact does this have on the intention-to-treat (ITT) analysis of the primary hard endpoints?

Key Response

A seasoned reviewer would flag that high crossover rates (patients failing medical therapy and requiring revascularization) dilute the treatment effect in an ITT analysis, strongly biasing the results toward the null for death and MI. The reviewer would likely request an as-treated or per-protocol analysis to estimate the true biological efficacy of the intervention, while acknowledging that ITT best reflects the real-world 'ischemia-guided' strategy being tested.

Guideline Committee

How do the findings from RITA 3 inform the current ACC/AHA and ESC guideline recommendations regarding the choice between an ischemia-guided versus an early invasive strategy in low-risk NSTE-ACS patients?

Key Response

Current ACC/AHA and ESC guidelines provide a Class I recommendation for an ischemia-guided strategy in low-risk NSTE-ACS patients (those without recurrent ischemia, heart failure, or dynamic ECG changes). RITA 3 is foundational to this recommendation, providing Level of Evidence A that an initial conservative approach is safe regarding hard endpoints (death/MI) in lower-risk cohorts, and that angiography can be safely reserved for those who develop recurrent or refractory symptoms.

Clinical Landscape

Noteworthy Related Trials

1999

FRISC-II Trial

n = 2,457 · Lancet

Tested

Early invasive strategy (routine angiography and revascularization within 7 days)

Population

Patients with non-ST-elevation acute coronary syndromes (unstable angina or NSTEMI)

Comparator

Non-invasive (conservative) strategy

Endpoint

Composite of death or myocardial infarction at 6 months

Key result: The early invasive strategy significantly reduced the composite of death or myocardial infarction at 6 months compared to the non-invasive strategy (9.4% vs 12.1%).

2001

TACTICS-TIMI 18 Trial

n = 2,220 · NEJM

Tested

Early invasive strategy (angiography within 4 to 48 hours) plus glycoprotein IIb/IIIa inhibitor tirofiban

Population

Patients with unstable angina or non-ST-segment elevation myocardial infarction

Comparator

Conservative strategy (angiography only for recurrent ischemia or positive stress test)

Endpoint

Composite of death, nonfatal myocardial infarction, or rehospitalization for ACS at 6 months

Key result: An early invasive strategy significantly reduced the primary composite endpoint (15.9% vs 19.4%), with the benefit primarily seen in patients with elevated troponin T levels.

2005

ICTUS Trial

n = 1,200 · NEJM

Tested

Routine early invasive strategy (angiography within 24 to 48 hours)

Population

Patients with non-ST-elevation acute coronary syndromes and an elevated cardiac troponin T level

Comparator

Selective invasive strategy (conservative approach with angiography only for refractory angina)

Endpoint

Composite of death, nonfatal myocardial infarction, or rehospitalization for angina within 1 year

Key result: There was no significant difference in the primary composite endpoint between the routine early invasive strategy and the selective invasive strategy (22.7% vs 21.2%).

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis